Sangamo Therapeutics (SGMOQ) EBT Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly EBT Margin of 266.88% for Q4 2025, up 9963.0% year-over-year from N/an in Q4 2024, and up 95.58% quarter-over-quarter from 6039.76% in Q3 2025.
Sangamo Therapeutics (SGMOQ) EBT Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics' EBT Margin history runs 16 years deep, the most recent figure standing at 266.88% for Q4 2025.
- In Q4 2025, EBT Margin rose 9963.0% year-over-year to 266.88%; the TTM figure through Dec 2025 stood at 312.25% (down 13937.0% YoY), while the FY2025 annual figure was 312.25%, down 14251.0% from the prior year.
- EBT Margin for Q4 2025 stood at 266.88%, up from 6039.76% in the prior quarter.
- The five-year high for EBT Margin was 21.78% in Q3 2024, with the low at 10185.24% in Q1 2024.
- The 5-year median for EBT Margin is 195.35% (2022), against an average of 1734.89%.
- The sharpest annual moves came in 2024 and 2025: EBT Margin sank 1019874 bps in 2024, then jumped 1001850 bps in 2025.
- Sangamo Therapeutics' EBT Margin stood at 134.22% in 2021, then slumped by 41 bps to 189.92% in 2022, then tumbled by 1462 bps to 2966.06% in 2023, then surged by 88 bps to 366.51% in 2024, then gained by 27 bps to 266.88% in 2025.
- Business Quant data shows SGMOQ's EBT Margin at 266.88% in Q4 2025, 6039.76% in Q3 2025, and 109.03% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -266.88% |
| Sep 30, 2025 | -6,039.76% |
| Jun 30, 2025 | -109.03% |
| Mar 31, 2025 | -473.48% |
| Dec 31, 2024 | -366.51% |
| Sep 30, 2024 | 21.78% |
| Jun 30, 2024 | -10,127.53% |
| Mar 31, 2024 | -10,185.24% |
| Dec 31, 2023 | -2,966.06% |
| Sep 30, 2023 | -1,094.84% |
| Jun 30, 2023 | -1,766.93% |
| Mar 31, 2023 | 13.50% |
| Dec 31, 2022 | -189.92% |
| Sep 30, 2022 | -200.77% |
| Jun 30, 2022 | -146.68% |
| Mar 31, 2022 | -155.57% |
| Dec 31, 2021 | -134.22% |
| Sep 30, 2021 | -166.66% |
| Jun 30, 2021 | -169.17% |
| Mar 31, 2021 | -173.81% |